Generation Bio Co
NASDAQ:GBIO
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.12
4.35
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one GBIO stock under the Base Case scenario is 1.12 USD. Compared to the current market price of 2.05 USD, Generation Bio Co is Overvalued by 45%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Generation Bio Co
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for GBIO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Generation Bio Co
Balance Sheet Decomposition
Generation Bio Co
Current Assets | 191.3m |
Cash & Short-Term Investments | 184.8m |
Receivables | 2.2m |
Other Current Assets | 4.3m |
Non-Current Assets | 57.5m |
Long-Term Investments | 15m |
PP&E | 37.2m |
Other Non-Current Assets | 5.3m |
Current Liabilities | 30.2m |
Accounts Payable | 1.7m |
Accrued Liabilities | 16.6m |
Other Current Liabilities | 11.9m |
Non-Current Liabilities | 114.2m |
Other Non-Current Liabilities | 114.2m |
Earnings Waterfall
Generation Bio Co
Revenue
|
18.6m
USD
|
Operating Expenses
|
-116.2m
USD
|
Operating Income
|
-97.7m
USD
|
Other Expenses
|
-47.8m
USD
|
Net Income
|
-145.5m
USD
|
Free Cash Flow Analysis
Generation Bio Co
USD | |
Free Cash Flow | USD |
GBIO Profitability Score
Profitability Due Diligence
Generation Bio Co's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Generation Bio Co's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
GBIO Solvency Score
Solvency Due Diligence
Generation Bio Co's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Generation Bio Co's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GBIO Price Targets Summary
Generation Bio Co
According to Wall Street analysts, the average 1-year price target for GBIO is 7.65 USD with a low forecast of 5.05 USD and a high forecast of 10.5 USD.
Dividends
Current shareholder yield for GBIO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
GBIO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Generation Bio Co. is a genetic medicine company focused on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 150 full-time employees. The company went IPO on 2020-06-12. The firm through its non-viral genetic medicine platform, is engaged in developing genetic medicines to provide genetic payloads, which include large and multiple genes to a range of cell types across a range of diseases. The company is comprised of three component technologies: ceDNA, ctLNP and ceDNA manufacturing process. ceDNA is an engineered, double-stranded, linear, covalently closed-ended deoxyribonucleic acid (DNA) construct, which includes the gene of interest and associated regulatory sequences. The company has produced ceDNA constructs of approximately eight kilobases. Its ctLNP delivery system builds upon clinically validated lipid nanoparticles and is designed to allow for repeat dosing of a genetic payload without stimulating an immune response, such as antibody production. Its ceDNA manufacturing process uses its own cell-free rapid enzymatic synthesis (RES) to produce ceDNA.
Contact
IPO
Employees
Officers
The intrinsic value of one GBIO stock under the Base Case scenario is 1.12 USD.
Compared to the current market price of 2.05 USD, Generation Bio Co is Overvalued by 45%.